Cryoport (NasdaqCM:CYRX) Q3 2025 Earnings Call November 04, 2025 05:00 PM ET Speaker4Good afternoon and welcome to Cryoport's Third Quarter 2025 earnings conference call. All participants will start in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. As a reminder, this call is being recorded. I will now turn the call over to your host, Todd Fromer, from KC ...

Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here’s a rundown of the temperature-controlled supply chain solutions company’s report.CYRX is holding steady in today’s choppy market. See if it is worth your attention here.Q3 Highlights: Cryoport reported third-quarter revenue of $44.2 million, beating analyst estimates of $41.36 million, according to Benzinga Pro. The company reported a third-quarter loss of 18 cents per share, beating estimates for a ...

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. This recognition demonstrates OXB’s excellence in quality, innov ...

OXB to participate in upcoming investor conferences and events Oxford, UK – 27 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial Officer, will participate in the following upcoming investor conferences and events. Details are provided below. Conferences Stifel Healthcare Conference (New York) Date: 11 November 202 ...

合作与资助公告 - ScaleReady与Wilson Wolf Manufacturing、Bio-Techne Corporation及CellReady合作，向儿童国家医院的四位教职人员授予了总额为37.5万美元的G-Rex资助 [1] - 资助旨在支持优化并将各种细胞和基因疗法计划转化到临床应用 [1] 具体资助项目详情 - Patrick Hanley博士获得10万美元，用于开发以G-Rex为核心的CAR-T细胞制造工艺，作为当前依赖复杂昂贵资本设备方法的灵活、经济替代方案 [2] - Michael Keller博士与Patrick Hanley博士共同获得15万美元，用于支持将其病毒特异性T细胞和肿瘤抗原相关T细胞制造工艺过渡到优化的G-Rex "M"系列生物反应器，实现功能封闭和半自动化生产 [3] - Amy Hont博士获得7.5万美元，用于支持其新型ATTACK TAAT细胞疗法的封闭系统G-Rex制造工艺开发与实施 [4] - Conrad Russell Cruz博士获得5万美元，用于支持优化以G-Rex为核心的CAR修饰TAAT细胞制造工艺 [4] G-Rex资助计划规模与影响 - ScaleReady的G-Rex资助计划已向受助者提供超过4000万美元的无成本产品承诺，单个资助奖项价值高达30万美元 [7] - 受助者还可获得ScaleReady不断增长的联盟合作伙伴的独家支持，涵盖cGMP生产、质量与监管事务、细胞和基因疗法业务运营等领域 [7] 行业倡议与平台采用 - ScaleReady与Hanson Wade合作推出名为LEAN Cell & Gene的免费活动系列，旨在帮助细胞和基因疗法实体系统识别并消除浪费、稳定业务运营、提高药品质量与供应 [8] - G-Rex制造平台目前已被超过800家组织使用，为约50%的细胞和基因疗法临床试验以及5种商业批准的细胞和基因疗法药物生产药品 [10] 合作公司背景 - Wilson Wolf Manufacturing致力于通过其可扩展的G-Rex技术简化细胞和基因疗法研究、工艺开发与制造 [12] - Bio-Techne Corporation是一家全球生命科学公司，与Wilson Wolf合作生产专门针对G-Rex生物反应器的培养基和细胞因子等产品 [13] - CellReady是全球首家且唯一一家以G-Rex为核心的合同开发与生产组织，专门从事基于G-Rex的细胞和基因疗法开发与制造 [14]

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clientsSupports existing near and medium-term financial guidance Oxford, UK – 7 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and ...

Key Takeaways CLPT introduced a robotic system integrating its neuro-navigation software with KUKA's arm.CLPT's platform targets biopharma partners launching complex brain-delivered cell and gene therapies.Collaborations and software focus reduce risk, speed timelines, and position CLPT for long-term growth.ClearPoint Neuro (CLPT) recently unveiled the development of its proprietary Robotic Neuro-Navigation System, a move that positions the company to contribute to robotics, neurosurgery, and advanced drug ...

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the Cell & Gene Meeting on the Mesa, taking place on October 7 in Phoenix, Arizona, and virtually online. “We are honored to participate in the Cell & Gene Meeting on the Mesa, one of the most important gatherings for advancing cell and gene therapies,” said Sanjeev Luther ...

文章核心观点 - 文章重点介绍了两只获得分析师“强力买入”评级且具备高增长潜力的低价股：Protara Therapeutics (TARA) 和 Alpha Teknova (TKNO) [3] 这两家公司均处于高增长行业，其股价因低于5美元而被归类为低价股，但分析师认为它们拥有三位数百分比的上涨空间 [6][7] Protara Therapeutics (TARA) 公司概况与产品管线 - Protara Therapeutics 是一家临床阶段生物技术公司，专注于开发癌症和罕见危及生命疾病的治疗方法 [2] - 公司核心产品管线包括两个候选药物：主导项目TARA-002，正在评估用于非肌层浸润性膀胱癌和淋巴管畸形；以及为需要肠外营养支持的患者设计的IV胆碱氯化物 [2] TARA-002 的作用机制与特点 - TARA-002是一种细胞疗法，其新颖之处在于源自一个遗传学上独特的化脓性链球菌细胞库，该库已在日本获批作为广谱免疫增强剂OK-432 [1] - 该疗法通过双重机制发挥作用：直接杀死肿瘤细胞，同时刺激称为免疫原性细胞死亡的免疫反应，从而放大抗肿瘤活性 [1] TARA-002 在非肌层浸润性膀胱癌领域的进展 - 公司正在通过一项名为ADVANCED-2的中期研究推进TARA-002用于非肌层浸润性膀胱癌 [8] - 早期结果显示：在对卡介苗无应答的患者组中，所有患者在6个月时均达到完全缓解，部分患者维持更长时间；在未接受过卡介苗治疗的患者中，大多数也显示出强效反应，部分患者保持无癌状态至少半年 [8] - 治疗迄今表现出良好的安全性，公司计划在2026年第一季度公布约25名可评估的卡介苗无应答患者的6个月中期结果 [8] TARA-002 在淋巴管畸形领域的进展 - 公司也将TARA-002的应用扩展到罕见儿科疾病淋巴管畸形，正在通过2期STARBORN-1试验进行评估 [9] - 在已完成的首个队列中，三名患者中有两名（一名巨囊型淋巴管畸形，一名舌下腺囊肿）在仅一次注射后即达到完全缓解，且疗法耐受性良好 [9] - 公司计划在2025年第四季度提供中期更新 [9] IV 胆碱氯化物项目的进展 - IV胆碱氯化物是公司针对依赖肠外支持、无法通过口服或肠内营养获得足够胆碱患者的磷脂底物替代疗法 [10] - 早期的THRIVE-1观察性研究强调了未满足的需求，显示大多数肠外支持患者缺乏胆碱且许多出现肝损伤迹象 [10] - 公司已启动THRIVE-3试验，这是一项现已开始的2b/3期注册试验，首例患者已开始给药 [10] Protara Therapeutics (TARA) 分析师观点与估值 - TD Cowen分析师Stacy Ku认为，鉴于TARA-002显示出令人鼓舞的迹象，且股价为3.19美元，现在是投资时机 [11] - 分析师指出，非肌层浸润性膀胱癌是TARA-002最大的市场机会，其对卡介苗无应答患者显示的12个月完全缓解率为67%，具有竞争力且安全性良好 [12] - 分析师认为TARA-002代表着一个超过5亿美元的潜在市场机会，给予“买入”评级和30美元的目标价，意味着未来一年有840%的上涨潜力 [12][13] - 华尔街共识评级为“强力买入”，基于5个买入评级，平均目标价24.20美元，隐含约659%的上涨潜力 [13] Alpha Teknova (TKNO) 公司业务概览 - Alpha Teknova 是一家在生命科学行业支持领域运营的公司，提供研究用途和临床级别的定制试剂、缓冲液、细胞培养基及相关产品，用于生物加工、诊断和分子生物学 [14] - 定制化是其服务的核心部分，帮助生物技术、诊断和学术研究领域的客户 [14] Alpha Teknova (TKNO) 产品应用与竞争优势 - 公司的产品线应用广泛，涵盖细胞和基因治疗、mRNA疗法、合成生物学和基因组学等热门领域 [15] - 公司拥有专有制造工艺，旨在以短交货时间大规模提供高质量的定制生物科学产品，能够满足从研究到商业化的所有规模和阶段订单 [15] - 公司的模块化制造设施和工艺为客户提供高效、可靠和可重复结果所需的高质量产品，应用范围从细胞培养到冷冻保存、提取纯化到分析 [16] Alpha Teknova (TKNO) 财务表现与展望 - 公司报告的第二季度收入为1030万美元，同比增长7.3%，比预期高出39万美元 [17] - 每股收益为亏损0.07美元，比预期好转0.03美元，毛利率从去年同期的约29.2%改善至约38.7%，临床解决方案部门增长约32% [17] - 公司重申其全年收入指引为3900万至4200万美元 [17] Alpha Teknova (TKNO) 分析师观点与估值 - Craig-Hallum分析师Matthew Hewitt指出，公司定位于从生物加工市场的快速增长中受益，通过为客户在数周内开发定制试剂，正迅速成为关键工具的优选供应商 [18][19] - 分析师给予“买入”评级和12美元的目标价，意味着一年内约159%的上涨潜力 [20] - 华尔街共识评级为“强力买入”，基于5份分析师评论（4买入1持有），股价4.64美元，平均目标价10美元暗示明年此时约有115%的涨幅 [20]

SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 3rd China Great Bay Cell and Gene Therapy Forum, taking place in Guangzhou, China, September 25-26, 2025. Dr. Song will d ...